Cerus Corporation (CERS)
| Market Cap | 439.32M +44.1% |
| Revenue (ttm) | 221.55M +15.1% |
| Net Income | -6.78M |
| EPS | -0.03 |
| Shares Out | 201.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,406,222 |
| Open | 2.260 |
| Previous Close | 2.260 |
| Day's Range | 2.170 - 2.288 |
| 52-Week Range | 1.380 - 3.470 |
| Beta | 1.83 |
| Analysts | Strong Buy |
| Price Target | 5.13 (+135.32%) |
| Est. Earnings | Nov 5, 2026 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do... [Read more]
Financial Performance
In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CERS stock is "Strong Buy." The 12-month stock price target is $5.13, which is an increase of 135.32% from the latest price.
News
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and I...
Cerus initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of Cerus (CERS) with a Buy rating and $6.50 price target The firm says the company has the only pathogen reduction platform with FDA approval and…
Cathie Wood’s ARK Investment buys 255K shares of Cerus today
20:07 EDT Cathie Wood’s ARK Investment buys 255K shares of Cerus (CERS) today
Cerus Earnings Call Transcript: Q2 2026
Q2 2026 saw 10% product revenue growth, strong U.S. and EMEA performance, and improved financials. Guidance for 2026 was raised, with IFC revenue expected to grow 40–50% year-over-year. Debt refinancing lowered costs and increased flexibility.
Cerus Earnings release: Q2 2026
Cerus released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Cerus Quarterly report: Q2 2026
Cerus has published its Q2 2026 quarterly earnings report on July 30, 2026.
Cerus Slides: Q2 2026
Cerus has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Cerus reports Q2 EPS (1c), two estimates (1c)
Reports Q2 revenue $63.3M, consensus $58.9M. “This quarter we made significant progress in expanding patient access to safer blood components around the globe,” said Vivek Jayaraman, Cerus (CERS)’ pre...
Cerus narrows FY26 revenue view to $229M-$231M, consensus $238.1M
The Company now expects full-year 2026 product revenue to be in the range of $229 million to $231 million, reflecting growth of 11% to 12% from 2025. Included in this…
Cerus Corporation Announces Second Quarter 2026 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. “This quarter we made s...
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the st...
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (I...
Cerus closes debt facility up to $110M
Cerus (CERS) Corporation announced the closing of a new debt facility with MidCap Financial, providing up to $110M. The facility consists of a 5-year term loan and an asset-backed revolving…
Cerus Corporation Closes New Debt Facility of Up to $110 Million
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consist...
Cerus Transcript: AGM 2026
The meeting confirmed a quorum, introduced leadership changes, and presented four proposals, all of which were approved by shareholders. No questions were submitted, and voting results will be reported on Form 8-K within four business days.
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company...
Cerus management to meet with Craig-Hallum
Meeting to be held in Chicago and Milwaukee on May 14 hosted by Craig-Hallum.
Cerus upgraded to Buy from Neutral at BTIG
BTIG upgraded Cerus (CERS) to Buy from Neutral with a $4 price target
Cerus Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% product revenue growth, driven by strong platelet and IFC demand, with raised full-year guidance and continued margin discipline. Innovation and new contracts in the U.S. and EMEA support long-term growth, despite inflation and regulatory uncertainties.
Cerus Earnings release: Q1 2026
Cerus released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Cerus Quarterly report: Q1 2026
Cerus has published its Q1 2026 quarterly earnings report on April 30, 2026.
Cerus reports Q1 EPS (1c), consensus (4c)
Reports Q1 revenue $59.9M, consensus $51.18M. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our…
Cerus raises FY26 product revenue view to $227M-$231M from $224M-$228M
Consensus $233.9M.
Cerus Corporation Announces First Quarter 2026 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong ...
Cerus announces new, four-year supply agreement with EFS
Cerus (CERS) Corporation announced the signing of a new, four-year supply agreement with Etablissement Francais du Sang, EFS, the French Blood Establishment, for the INTERCEPT Blood System. The agreem...